New "Epocrates Bugs + Drugs" App Harnesses Big Data for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
New "Epocrates Bugs + Drugs" App Harnesses Big Data for Better, Personalized Patient Care

SANTA CLARA, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) -- According to a report recently issued by the Centers for Disease Control and Prevention (CDC), every year more than two million people in the U.S. contract infections that are resistant to antibiotics and at least 23,000 people die as a result. Antibiotic resistant bacteria or "superbugs" such as resistant E. coli and staph are of great concern because they are increasingly impervious to typical antibiotics. To compound the problem, many clinicians who work outside of hospitals are unaware of the bacteria types pervasive in their local areas. Today, from the 7th Annual Health 2.0 Conference in Santa Clara, California, athenahealth, Inc. (Nasdaq: ATHN ) and Epocrates together announced a new, free mobile app, "Epocrates Bugs + Drugs," to arm clinicians with timely geolocated information about bacteria types and resistance patterns, and to support appropriate antibiotic prescribing.

"Epocrates Bugs + Drugs is a game-changer in the clinical toolbox. Traditionally, hospitals have tracked resistance trends on inpatients. Now, Bugs + Drugs goes beyond the hospital setting, transforming lab results from athenahealth's cloud-based EHR database of 15 million patients into geotargeted data to help physicians identify common and uncommon bugs in the communities where their patients live. Clinicians can access critical resistance information to formulate the best treatment plan.  It's one step closer to personalized medicine," said Dr. Anne Meneghetti, Executive Director of Medical Information at Epocrates, an athenahealth company. "This app is a perfect example of pairing athenahealth's big data with Epocrates' mobile expertise to better equip caregivers to make confident and efficient decisions in the moments of care. Decisions made in those moments can affect future antibiotic resistance for the entire population." 

"The convenience of this app with its localized content provides great insights from an infectious diseases perspective. The real-time, geographic-specific information of the proportions of specific organisms for a particular type of infection and the susceptibility profiles of those organisms allows for more prudent use of antibiotics, which is a major benefit to the patient and the health system," said Dr. Rajesh Gupta, Infectious Disease Specialist.

To use the app, health care providers simply enter their patient's location, then intuitively view bacteria common to the area and explore potential bacterial resistance patterns. Epocrates Bugs + Drugs features:

  • Lists of bacteria observed in urine, blood, and skin for geolocated communities across the country
  • Antibiotic drug options organized by organism susceptibility
  • Epocrates' trusted drug content, including dosing and contraindication information with links to complete monographs
  • Continual updates from athenahealth's cloud-based EHR database
  • A sleek, image-rich interface designed specifically for Apple's iOS 7 operating system

"Epocrates Bugs + Drugs delivers a beautiful, differentiated user experience," added Abbe Don, Vice President of User Experience at Epocrates. "Health care professionals have been longing for an app experience like this."

Epocrates Bugs + Drugs is now available at no cost for iOS 7 devices in the Apple App Store: http://bit.ly/18uyL3n

About Epocrates, Inc.

Epocrates, Inc., an athenahealth company, is recognized for developing the #1 medical application among U.S. physicians for clinical content, practice tools, and health industry engagement at the point of care. Epocrates has established a loyal network of more than one million health care professionals, including 50 percent of U.S. physicians, who routinely use its intuitive solutions to help streamline workflow and improve patient care. For more information, please visit www.epocrates.com/company .

About athenahealth, Inc.

athenahealth is a leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination. athenahealth's mission is to be caregivers' most trusted service, helping them do well doing the right thing. For more information, please visit www.athenahealth.com .

About Health 2.0

Health 2.0 promotes, showcases, and catalyzes new technologies in health care through a worldwide series of conferences, code-a-thons, prize challenges, and more. We also have the leading market intelligence on new health technology companies. For more information on Health 2.0, please visit our web site http://www.health2con.com

Apple is a registered trademark and App Store is a registered service mark of Apple Inc.

Holly Spring athenahealth, Inc. (Media) 617-402-1631 April Marks Epocrates, Inc. (Media) 650-520-2413 Dana Quattrochi athenahealth, Inc. (Investors) 617-402-1329

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 21

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 26

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Crypto Developments: Circle's Blockchain, Ethereum Bets, and More

Updated Category News Views 251

The Current Landscape of Cryptocurrency The last week in the world of cryptocurrency and finance has been nothing less than exhilarating. With significant developments, including the launch of a new blockchain by Circle Internet Group Inc. and major investments in Ethereum, there is plenty to discuss. Let’s explore the most noteworthy stories that are shaping the crypto...

Continue Reading
ezPaycheck 2025 Payroll Software: Cost-Effective Compliance Solution

Updated Category News Views 132

ezPaycheck 2025: The Efficient Payroll Solution The new ezPaycheck 2025 payroll software is now available, offering businesses an excellent in-house solution for payroll processing that is both compliant and economical. This updated version comes with essential features designed to make payroll management easier than ever. Priced at just $169 for a single installation,...

Continue Reading
Investors of Applied Therapeutics, Inc. Should Take Action Now

Updated Category News Views 188

Understanding the Securities Fraud Allegations Against Applied Therapeutics Applied Therapeutics, Inc. (APLT) has found itself at the heart of a securities fraud class action lawsuit. This legal proceeding has been announced by The Law Offices of Frank R. Cruz as they represent investors who acquired shares during a significant time frame. The legal challenge highlights...

Continue Reading
Ardagh Metal Packaging Reports Positive Year-End 2024 Results

Updated Category News Views 148

Ardagh Metal Packaging's Year-End 2024 Results Ardagh Metal Packaging S.A. (NYSE: AMBP) recently reported their impressive results for the full year and fourth quarter of 2024. The company's performance is a reflection of strategic growth and resilience in a challenging market environment. Quarterly and Annual Performance Overview For the fourth quarter of 2024, Ardagh...

Continue Reading
Empowering Voices: The Call to Protect Our Children

Updated Category News Views 243

Making a Stand Against Child Trafficking In a heartfelt initiative, ThinkCareBelieve has announced a powerful call to action aimed at ensuring the safety and protection of children across the nation. This initiative addresses the urgent concern of child trafficking and the plight of missing children, many of whom have been smuggled through borders and placed in unsafe...

Continue Reading